

Informazione Regolamentata n. 20279-2-2026	Data/Ora Inizio Diffusione 10 Febbraio 2026 15:17:02	Euronext Growth Milan
--	---	-----------------------

Societa' : VALTECNE

Utenza - referente : VALTECNENSS01 - -

Tipologia : REGEM

Data/Ora Ricezione : 10 Febbraio 2026 15:17:02

Data/Ora Inizio Diffusione : 10 Febbraio 2026 15:17:02

Oggetto : THE BOARD OF DIRECTORS OF VALTECNE
S.P.A. REVIEWS SALES REVENUES AS AT
31 DECEMBER 2025

Testo del comunicato

Vedi allegato

PRESS RELEASE

THE BOARD OF DIRECTORS OF VALTECNE S.P.A. REVIEWS SALES REVENUES AS AT 31 DECEMBER 2025

CONSOLIDATED REVENUES OF € 35.7 MILLION

STRONGER FOCUS ON THE MEDICAL SECTOR AND GROWTH IN THE ORTHOPAEDIC CORE BUSINESS IN 2025

Berbenno di Valtellina (SO), 10 February 2025 – The Board of Directors of **Valtecne S.p.A.** (ISIN IT0005532525, ticker VLT.IM) – a company operating in the field of high-precision mechanics for medical devices and industrial applications – met today and reviewed the sales revenues as at 31 December 2025, which have not been subject to audit. Consolidated revenues amounted to € 35.7 million (€ 36.9 million as at 31 December 2024), while stand-alone revenues totalled € 30.1 million (€ 30.4 million as at 31 December 2024).

Paolo Mainetti, Chief Executive Officer of Valtecne, commented: *“The 2025 results confirm the strength of our strategic path and the progressive consolidation of our medical core business, which today represents the Group’s main growth driver. The expansion of the orthopaedic segment and the gradual strengthening of the order backlog highlight structurally solid demand, which is not yet fully reflected in revenues, also due to seasonal dynamics related to supply contracts under vendor-managed inventory arrangements. In this context, the appointment of Fabio Esposito as new General Manager and Luigi Ferrari as a member of the Board of Directors and Senior Advisor represents a key step in supporting future growth, strengthening the organisational structure, and enhancing opportunities in the medical market. We look to the medium to long term with confidence, supported by a distinctive competitive positioning and further strengthened governance”.*

Below is a breakdown of consolidated and stand-alone revenues for fiscal year 2025 and the corresponding period in 2024.

CONSOLIDATED					
SALES REVENUES (€/thousands)	31/12/2025	% of Total	31/12/2024 Pro-forma	% of Total	Change %
Medical Business Line	26,167	73.3%	26,737	72.4%	-2.1%
Industrial Business Line	9,519	26.7%	10,179	27.6%	-6.5%
Total	35,686	100%	36,917	100%	-3.3%

STAND ALONE					
SALES REVENUES (€/thousands)	31/12/2025	% of Total	31/12/2024	% of Total	Change %
Medical Business Line	22,554	75%	21,258	70%	6.1%
Industrial Business Line	7,550	25%	9,137	30%	-17.4%
Total	30,104	100%	30,395	100%	-1.0%

At consolidated level, in 2025 the **Medical business line** generated revenues of € 26.2 million, down slightly by 2.1% compared to fiscal year 2024, while maintaining a 73.3% share of total revenues. This performance reflects, on the one hand, the normalisation of volumes recorded by the subsidiary Utilità in the dental segment and, on the other, the effects of supply contracts under vendor-managed inventory arrangements, which tend to influence the timing of revenue recognition. In this context, revenue trends do not yet fully reflect the double-digit growth in production volumes of the orthopaedic core business, which continued to strengthen during the year, supported by robust market demand and a progressively consolidating order backlog. The **Industrial business line** reported revenues of € 9.5 million, down 6.5% compared to 2024, falling below the € 10 million threshold for the first time since 2021, in line with the Group's increasing strategic focus on the medical sector.

On a stand-alone basis, Valtecne recorded revenues in the **Medical business line** of € 22.6 million, up 6.1% year-on-year, accounting for 75% of total revenues, confirming the strength of its competitive positioning in the orthopaedic segment. Revenues from the **Industrial business line** amounted to € 7.6 million, down 17.4%.

The evolution of the business mix confirms the ongoing shift towards the medical sector, which represents the Group's main growth driver in the medium to long term and continues to be the primary focus of industrial and commercial investments.

* * *

This press release is also available on the Company's website www.valtecne.com (section "Investors") and on <https://www.emarketstorage.it/>.

* * *

About Valtecne

Founded in 1983, Valtecne is a leading company in high-precision mechanics. It manufactures components used in the medical sector – particularly surgical instruments for orthopedics and implantable components – as well as in various industrial sectors such as



power transmission, automotive, and energy. As of 31 December 2024, Valtecne reported Production Value of €29.9 million and Adjusted EBITDA of €7.5 million, corresponding to an EBITDA margin of 25.1%.

Contacts:

Euronext Growth Advisor – CFO SIM S.p.A.

ecm@cfosim.com

Phone. + 02 30343 1

Ufficio Stampa Corporate – CDR Communication

Martina Zuccherini martina.zuccherini@cdr-communication.it

Specialista – MIT SIM

trading-desk@mitsim.it

Phone +39 02 305 612 70

